LFA
CORT icon

LGT Financial Advisors’s Corcept Therapeutics CORT Stock Holding History

LGT Financial Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-237
Closed -$11.9K – 391
2024
Q4 		$11.9K Hold
237
– – 0.03% 407
2024
Q3 		$11K Hold
237
– – 0.03% 402
2024
Q2 		$7.7K Hold
237
– – 0.02% 521
2024
Q1 		$5.97K Hold
237
– – 0.01% 592
2023
Q4 		$7.7K Hold
237
– – 0.01% 537
2023
Q3 		$6.46K Buy
+237
New +$6.86K 0.01% 569

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

LGT Financial Advisors's CORT Position: Q1 2025 in Review

LGT Financial Advisors sold out of Corcept Therapeutics (CORT) in Q1 2025, closing a stake of 237 shares — an estimated $11.9K sold.

LGT Financial Advisors first reported a position in CORT in Q3 2023 and held it in 6 quarters. The position peaked at $11.9K in Q4 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q1 2025.

  • LGT Financial Advisors reported no remaining Corcept Therapeutics position as of Q1 2025 after selling out during the quarter.
  • LGT Financial Advisors sold 237 Corcept Therapeutics shares in Q1 2025, an estimated $11.9K.
  • LGT Financial Advisors first reported a position in Corcept Therapeutics in Q3 2023 and held it in 6 quarters.
  • LGT Financial Advisors's Corcept Therapeutics position peaked at $11.9K in Q4 2024.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2025.

Based on LGT Financial Advisors's 13F filing for Q1 2025, filed 8 May 2025.